National Research (NASDAQ:NRC) Stock Crosses Above 200 Day Moving Average – Time to Sell?

Shares of National Research Corporation (NASDAQ:NRC) passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $16.45 and traded as high as $17.60. National Research shares last traded at $17.11, with a volume of 112,562 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings downgraded shares of National Research from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, March 6th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has an average rating of “Sell”.

National Research Price Performance

The stock has a market capitalization of $389.25 million, a price-to-earnings ratio of 34.22 and a beta of 0.39. The company has a quick ratio of 0.55, a current ratio of 0.55 and a debt-to-equity ratio of 5.36. The business’s 50 day simple moving average is $16.03 and its 200-day simple moving average is $16.45.

National Research (NASDAQ:NRC) last announced its quarterly earnings data on Tuesday, February 3rd. The company reported $0.16 earnings per share (EPS) for the quarter. The firm had revenue of $35.19 million for the quarter. National Research had a net margin of 8.44% and a return on equity of 103.84%.

Institutional Investors Weigh In On National Research

A number of large investors have recently bought and sold shares of the company. Hotchkis & Wiley Capital Management LLC grew its stake in National Research by 7.9% during the third quarter. Hotchkis & Wiley Capital Management LLC now owns 292,400 shares of the company’s stock worth $3,737,000 after buying an additional 21,450 shares in the last quarter. AQR Capital Management LLC grew its stake in National Research by 86.2% during the second quarter. AQR Capital Management LLC now owns 201,396 shares of the company’s stock worth $3,383,000 after buying an additional 93,262 shares in the last quarter. Willis Investment Counsel grew its stake in National Research by 1.6% during the fourth quarter. Willis Investment Counsel now owns 183,226 shares of the company’s stock worth $3,439,000 after buying an additional 2,920 shares in the last quarter. Bank of America Corp DE boosted its stake in shares of National Research by 5.8% in the 2nd quarter. Bank of America Corp DE now owns 122,344 shares of the company’s stock valued at $2,055,000 after purchasing an additional 6,690 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of National Research by 18.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 114,967 shares of the company’s stock valued at $2,158,000 after purchasing an additional 18,067 shares in the last quarter. 47.26% of the stock is currently owned by institutional investors and hedge funds.

National Research Company Profile

National Research Corp (NASDAQ: NRC), also known as NRC Health, is a healthcare analytics and performance improvement company specializing in patient and employee experience measurement. The company’s cloud-based platform enables healthcare providers to collect real-time feedback through patient satisfaction surveys, post-discharge outreach, and employee engagement tools. NRC Health integrates clinical, operational and financial data to deliver actionable insights that support quality improvement initiatives and value-based care programs.

Since its founding in the early 1990s and headquartered in Lincoln, Nebraska, National Research has expanded beyond its regional roots to serve more than 1,600 hospitals and 12,000 care sites across the United States and Canada.